Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | LPL | P06858 | 1/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TDP2 | O95551 | 1/20 | 0.32 |
| ▸ | NSD2 | O96028 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.32 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.31 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.31 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.31 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.31 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.31 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3938364 | 0.88 | CA2 (0.43) | CA2LPLLIPGENPP2ORAI1 | |
| SCHEMBL21642587 | 0.80 | ENPP2 (0.31) | TRPA1ATMENPP2ORAI1ORAI2 | |
| SCHEMBL28779629 | 0.80 | CYP1A2 (0.33) | TRPA1ATMCYP1A2CYP2A6TSHR | |
| SCHEMBL3199130 | 0.79 | ALDH1A1 (0.42) | CA2LPLLIPGTRPA1ATM | |
| SCHEMBL7776316 | 0.79 | TRPA1 (0.37) | CA2LPLLIPGTRPA1ATM | |
| SCHEMBL7242031 | 0.79 | TRPA1 (0.37) | CA2LPLLIPGTRPA1ATM | |
| SCHEMBL21384955 | 0.77 | POLB (0.41) | CA2LPLLIPGTRPA1ATM | |
| SCHEMBL5917526 | 0.77 | CA2 (0.37) | CA2LPLLIPGORAI1ORAI2 | |
| SCHEMBL5250130 | 0.77 | POLB (0.52) | CA2LPLLIPGTSHRKDM4E | |
| SCHEMBL12877656 | 0.77 | CA2 (0.32) | CA2LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115928264-A | Preparation method of metal-containing near-stoichiometric continuous silicon carbide fiber | 湖南泽睿新材料有限公司 | 2023-04-07 | — | — | CN | claimed |
| US-8921299-B2 | Detergents having acceptable color | THE PROCTER & GAMBLE COMPANY (US) | 2014-12-30 | — | — | US | claimed |
| CN-119716054-A | Fluorescent paper chip for detecting staphylococcus aureus and preparation method and application thereof | 南京师范大学 | 2025-03-28 | — | — | CN | disclosed |
| CN-119716050-A | Fluorescent paper chip for detecting escherichia coli O157: H7 as well as preparation method and application thereof | 南京师范大学 | 2025-03-28 | — | — | CN | disclosed |
| CN-119192137-A | Inhibition of human integrin alpha4β7 | 莫菲克医疗股份有限公司 | 2024-12-27 | — | — | CN | disclosed |
| CN-112682031-B | Oil field interwell tracer, tracing method and fracturing fluid | 中国石油化工股份有限公司 | 2024-06-28 | — | — | CN | disclosed |
| WO-2024126697-A1 | HIGH STRENGTH LIQUID PROTEASE FORMULATIONS | NOVOZYMES A/S (DK) | 2024-06-20 | — | — | WO | disclosed |
| EP-4379029-A1 | POLYPEPTIDES AND COMPOSITIONS COMPRISING SUCH POLYPEPTIDES | Novozymes A/S (DK) | 2024-06-05 | — | — | EP | disclosed |
| EP-3647398-B1 | CLEANING COMPOSITIONS CONTAINING DISPERSINS V | HENKEL AG & CO KGAA (DE) | 2024-05-15 | — | — | EP | disclosed |
| US-20240132808-A1 | Storage-Stable Hydrolase Containing Liquids | BASF SE (DE) | 2024-04-25 | — | — | US | disclosed |
| EP-4305146-A1 | POLYPEPTIDE VARIANTS | Novozymes A/S (DK) | 2024-01-17 | — | — | EP | disclosed |
| WO-2007025549-A1 | STABILIZATION OF CONCENTRATED LIQUID ENZYME ADDITIVES | NOVOZYMES A/S (DK) | 2007-03-08 | — | — | WO | disclosed |
| EP-1341793-B1 | CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES INC (US) | 2007-01-17 | — | — | EP | disclosed |
| EP-1732541-A2 | CYCLIC COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005099688-A2 | CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-10-27 | — | — | WO | disclosed |
| US-20040266799-A1 | CRF receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. | 2004-12-30 | — | — | US | disclosed |
| US-6747034-B2 | CORTICOTROPIN-RELEASING FACTOR (CRF); SUCH AS 4-CHLORO-2-METHYL-5-NITRO-8-(2,4-DICHLORO)PHENYL-1,7-NAPHTHYRIDINE FOR TREATING STROKE, ANXIETY, DEPRESSION, AND/OR IRRITABLE BOWEL SYNDROME | NEUROCRINE BIOSCIENCES, INC. | 2004-06-08 | — | — | US | disclosed |
| EP-1341793-A2 | CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | Neurocrine Biosciences, Inc. (US) | 2003-09-10 | — | — | EP | disclosed |
| US-20020151557-A1 | CRF receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC | 2002-10-17 | — | — | US | disclosed |
| WO-2002040480-A2 | CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266799-A1 | CRF receptor antagonists and methods relating thereto | CRHR1, CRH, CRHR2 | CA2 715/4885LPL 2041/4885LIPG 1114/4885 |
| US-20020151557-A1 | CRF receptor antagonists and methods relating thereto | CRHR1, CRH, CRHR2 | CA2 715/4885LPL 2041/4885LIPG 1114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.